Abstract
Cardiovascular disease remains the leading cause of death worldwide. The renin-angiotensin-aldosterone system (RAAS) plays a key role in the regulation of blood pressure, through the actions of angiotensin (Ang) II. Excessive RAAS activity may lead to hypertension and associated target organ damage. Indeed, RAAS blockade with angiotensin converting enzyme inhibitors (ACEIs) and/or angiotensin receptor AT (1) blockers (ARBs) has proved to be successful treatment for arterial hypertension, heart failure and diabetes. Accumulating evidence suggests that arterial stiffness is an important and independent predictor of cardiovascular risk. More recently, a role for advanced glycation end-products (AGEs) in the development of arterial stiffening has been suggested. Advanced glycation end-products form by a nonenzymatic reaction between reducing sugars and biological proteins. Mechanisms underlying these alterations include AGE cross-linking of collagen and AGE interactions with circulating proteins and AGE receptors. New pharmacologic agents that prevent AGE formation, break cross-links, or block AGE receptors reduce vascular and myocardial stiffness, inhibit atherosclerotic plaque formation, and improve endothelial function. These agents promise to reduce the risk of isolated systolic hypertension, diastolic dysfunction, diabetes and thus, heart failure.
Keywords: Advanced glycation end products (AGEs), hypertension, diabetes, renin-angiotensin-aldosterone system (RAAS), arterial stiffness, AGE cross-link breakers, renin inhibitors
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Inhibition of Renin-Angiotensin System and Advanced Glycation End Products Formation: A Promising Therapeutic Approach Targeting on Cardiovascular Diseases
Volume: 5 Issue: 4
Author(s): A. Geronikaki, A. Gavalas, V. Dislian and G. Giannoglou
Affiliation:
Keywords: Advanced glycation end products (AGEs), hypertension, diabetes, renin-angiotensin-aldosterone system (RAAS), arterial stiffness, AGE cross-link breakers, renin inhibitors
Abstract: Cardiovascular disease remains the leading cause of death worldwide. The renin-angiotensin-aldosterone system (RAAS) plays a key role in the regulation of blood pressure, through the actions of angiotensin (Ang) II. Excessive RAAS activity may lead to hypertension and associated target organ damage. Indeed, RAAS blockade with angiotensin converting enzyme inhibitors (ACEIs) and/or angiotensin receptor AT (1) blockers (ARBs) has proved to be successful treatment for arterial hypertension, heart failure and diabetes. Accumulating evidence suggests that arterial stiffness is an important and independent predictor of cardiovascular risk. More recently, a role for advanced glycation end-products (AGEs) in the development of arterial stiffening has been suggested. Advanced glycation end-products form by a nonenzymatic reaction between reducing sugars and biological proteins. Mechanisms underlying these alterations include AGE cross-linking of collagen and AGE interactions with circulating proteins and AGE receptors. New pharmacologic agents that prevent AGE formation, break cross-links, or block AGE receptors reduce vascular and myocardial stiffness, inhibit atherosclerotic plaque formation, and improve endothelial function. These agents promise to reduce the risk of isolated systolic hypertension, diastolic dysfunction, diabetes and thus, heart failure.
Export Options
About this article
Cite this article as:
Geronikaki A., Gavalas A., Dislian V. and Giannoglou G., Inhibition of Renin-Angiotensin System and Advanced Glycation End Products Formation: A Promising Therapeutic Approach Targeting on Cardiovascular Diseases, Cardiovascular & Hematological Agents in Medicinal Chemistry 2007; 5 (4) . https://dx.doi.org/10.2174/187152507782109926
DOI https://dx.doi.org/10.2174/187152507782109926 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Mitochondrial Approach to Cardiovascular Risk and Disease
Current Pharmaceutical Design Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Detection of Myocardial Ischemia in Patients with Blunted Hemodynamic Response to Adenosine Stress
Current Medical Imaging Editorial (Thematic Issue: Novel Inflammatory Biomarkers in Cardiovascular Disease: From Molecular Mechanisms to Therapeutic Targets (Part-II))
Current Medicinal Chemistry Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future
Current Pharmaceutical Design Preface [Hot Topic: Treatment of Hypertension, Its Pathophysiology and the Clinical Use of Antihypertensive Drugs (Executive Editor: Gregory Y.H. Lip)]
Current Pharmaceutical Design Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design Polyphenols Regulate Endothelial Functions and Reduce the Risk of Cardiovascular Disease
Current Pharmaceutical Design Nitroso-Redox Balance and Modulation of Basal Myocardial Function: An Update from the Italian Society of Cardiovascular Research (SIRC)
Current Drug Targets Novel C-9, 9'-O-acyl Esters of (-)-Carinol as Free-radical Scavengers and Xanthine Oxidase Enzyme Inhibitors: Synthesis and Biological Evaluation
Medicinal Chemistry Biomaterials and Mesenchymal Stem Cells for Regenerative Medicine
Recent Patents on Biotechnology Unfolding Cardiac Amyloidosis –From Pathophysiology to Cure
Current Medicinal Chemistry Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors
Current Drug Targets Neuropeptide Mimetics and Antagonists in the Treatment of Inflammatory Disease: Focus on VIP and PACAP
Current Topics in Medicinal Chemistry Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology Season of Birth Effects on Reproduction in Women
Current Women`s Health Reviews Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Snake Venom Proteins Isolated from Tunisian Vipers: Pharmacological and Therapeutic Overview
Venoms and Toxins Inflammatory Mechanisms in Myocardial Infarction
Current Drug Targets - Inflammation & Allergy